Abstract:The significance of pan-cancer categories has recently been recognized as widespread in cancer research. Pan-cancer categorizes a cancer based on its molecular pathology rather than an organ. The molecular similarities among multi-omics data found in different cancer types can play several roles in both biological processes and therapeutic developments. Therefore, an integrated analysis for various genomic data is frequently used to reveal novel genetic and molecular mechanisms. However, a variety of algorithms for multi-omics clustering have been proposed in different fields. The comparison of different computational clustering methods in pan-cancer analysis performance remains unclear. To increase the utilization of current integrative methods in pan-cancer analysis, we first provide an overview of five popular computational integrative tools: similarity network fusion, integrative clustering of multiple genomic data types (iCluster), cancer integration via multi-kernel learning (CIMLR), perturbation clustering for data integration and disease subtyping (PINS) and low-rank clustering (LRACluster). Then, a priori interactions in multi-omics data were incorporated to detect prominent molecular patterns in pan-cancer data sets. Finally, we present comparative assessments of these methods, with discussion over key issues in applying these algorithms. We found that all five methods can identify distinct tumor compositions. The pan-cancer samples can be reclassified into several groups by different proportions. Interestingly, each method can classify the tumors into categories that are different from original cancer types or subtypes, especially for ovarian serous cystadenocarcinoma (OV) and breast invasive carcinoma (BRCA) tumors. In addition, all clusters of the five computational methods show notable prognostic values. Furthermore, both the 9 recurrent differential genes and the 15 common pathway characteristics were identified across all the methods. The results and discussion can help the community select appropriate integrative tools according to different research tasks or aims in pan-cancer analysis.

Multi-cancer molecular signatures and their interrelationships

A Common Gene Expression Signature Analysis Method for Multiple Types of Cancer

Approaches to Uncovering Cancer Diagnostic and Prognostic Molecular Signatures.

Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis

Molecular Signature of Cancer at Gene Level or Pathway Level? Case Studies of Colorectal Cancer and Prostate Cancer Microarray Data.

Investigating Multi-Cancer Biomarkers And Their Cross-Predictability In The Expression Profiles Of Multiple Cancer Types

Multi-study Integration of Brain Cancer Transcriptomes Reveals Organ-Level Molecular Signatures

Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data

Joint Analysis Of Expression Profiles From Multiple Cancers Improves The Identification Of Microrna-Gene Interactions

Identification of Cancer Trait Genes and Association Analysis under Pan-Cancer

Comprehensive cross cancer analyses reveal mutational signature cancer specificity

Exploring Epigenetic Biomarkers of Universal Specificities and Commonalities among Pan-Cancer Cohorts in the Cancer Genome Atlas.

Gene signatures for cancer research: A 25-year retrospective and future avenues

Multiclass cancer diagnosis using tumor gene expression signatures

Identification of Common Tumor Signatures Based on Gene Set Enrichment Analysis.

Survey and Comparative Assessments of Computational Multi-Omics Integrative Methods with Multiple Regulatory Networks Identifying Distinct Tumor Compositions Across Pan-Cancer Data Sets

Identification of Pan-Cancer Biomarkers Based on the Gene Expression Profiles of Cancer Cell Lines

Abstract SY12-03: Multi-tumor Analysis of TCGA Data Identifies Expression Commonalities Across Tumor Types.

Detecting microbiome species unique or enriched in 20+ cancer types and building cancer microbiome heterogeneity networks

Multi-omics Characterization and Validation of MSI-related Molecular Features Across Multiple Malignancies